Hypercholesterolemia is a major risk factor for the development of coronary heart disease.
HMG-CoA reductase inhibitors have been used as first-line drugs because of both their …

Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …

Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …

Background: High levels of total and LDL-cholesterol are associated with an increased risk
of atherosclerotic vascular disease. Lowering of serum cholesterol levels by pharmacologic …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

Abstract By inhibiting 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase, the
statins reduce hepatocyte cholesterol levels, which results in up-regulation of low-density …

Lowering of serum cholesterol levels by pharmacologic intervention with statins reduces the
incidence of cardiovascular events in subjects with and without atherosclerotic …

OBJECTIVE: To review the efficacy and safety of atorvastatin in the treatment of
dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current …

Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …

The introduction of statins has drastically changed the treatment and prevention of
atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary …